The overall goal of the Clinical Protocol and Data Management (CPDM) resource at Roswell Park is to assist investigators in the development, implementation, conduct, completion, and reporting of clinical trials in a scientifically rigorous and regulatory compliant manner. This goal is carried out by the Clinical Research Services, a centralized resource that oversees a broad portfolio of clinical trials, including institutional trials (investigator-initiated or IIT), national clinical trial network, other NCI-sponsored trials, and industry-sponsored trials. CRS provides infrastructure for all clinical research activities. CPDM staff assist investigators in assembling clinical and scientific content of protocols and developing budgets, as well as facilitating timely and effective protocol review and implementation. CPDM oversight of clinical research studies includes submission of the protocol, amendments, and continuing reviews to the Scientific Review Committee and the Institutional Review Board, and the management and tracking of all regulatory documents. CPDM staff provides administrative support to the Clinical Disease Teams for protocol prioritization and ongoing scientific relevance and the Data Safety Monitoring Committee. CPDM staff assist investigators in documentation of adverse events, outcomes, informed consent, accrual, and data items critical for safeguarding human subjects. CPDM ensures complete and accurate study data by entering the data in a centralized electronic research database. CPDM ensures that all adverse events and their attributions are reported promptly and accurately to the required internal and external regulatory agencies, and provides study sponsors and regulatory agencies with all required study documents. The CPDM has four specific aims: 1. Provide a central infrastructure including a clinical trial management system and technical staff to support Roswell Park investigators in their efforts to promote efficient and effective clinical trial development, activation, and outcome reporting. 2. Ensure clinical research performance in accordance with applicable regulations, policies, and procedures by providing training, and education. 3. Provide appropriate oversight and monitoring of all cancer-related Roswell Park clinical trials, ensuring participant safety, validity and integrity of the data collected, and quality control. 4. Coordinate and cultivate partnerships to promote and facilitate access and implementation of clinical trials within the Roswell Park catchment area, state of New York, and beyond.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016056-43
Application #
9923592
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-05-01
Budget End
2021-04-30
Support Year
43
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Mayor, Paul C; Eng, Kevin H; Singel, Kelly L et al. (2018) Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry. J Allergy Clin Immunol 141:1028-1035
Dasgupta, Subhamoy; Rajapakshe, Kimal; Zhu, Bokai et al. (2018) Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer. Nature 556:249-254
La Shu, Shin; Yang, Yunchen; Allen, Cheryl L et al. (2018) Metabolic reprogramming of stromal fibroblasts by melanoma exosome microRNA favours a pre-metastatic microenvironment. Sci Rep 8:12905
Zhang, Dingxiao; Tang, Dean G; Rycaj, Kiera (2018) Cancer stem cells: Regulation programs, immunological properties and immunotherapy. Semin Cancer Biol 52:94-106
Gabriel, Emmanuel; Attwood, Kristopher; Al-Sukhni, Eisar et al. (2018) Age-related rates of colorectal cancer and the factors associated with overall survival. J Gastrointest Oncol 9:96-110
Ma, Wen Wee; Xie, Hao; Fetterly, Gerald et al. (2018) A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients. Am J Clin Oncol :
Chen, George L; Carpenter, Paul A; Broady, Raewyn et al. (2018) Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease. Biol Blood Marrow Transplant 24:373-380
Eng, Kevin H; Szender, J Brian; Etter, John Lewis et al. (2018) Paternal lineage early onset hereditary ovarian cancers: A Familial Ovarian Cancer Registry study. PLoS Genet 14:e1007194
Barger, Carter J; Zhang, Wa; Sharma, Ashok et al. (2018) Expression of the POTE gene family in human ovarian cancer. Sci Rep 8:17136
Bucsek, Mark J; Giridharan, Thejaswini; MacDonald, Cameron R et al. (2018) An overview of the role of sympathetic regulation of immune responses in infectious disease and autoimmunity. Int J Hyperthermia 34:135-143

Showing the most recent 10 out of 1555 publications